Malignant mixed Müllerian tumor of the uterus associated with tamoxifen therapy for breast cancer

Magnani, KK; Dubey, Suparna; Rai, Sunita

doi:10.4103/0377-4929.72038

Cited by 4 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumour characteristics such as myometrial invasion of less than one-third of the uterus with no detectable metastasis, and a size less than 7 cm are all associated with a favourable outcome in some reports [73]. Most studies agree that deeper myometrial invasion increases the risk of extrauterine extension [30] and on multivariant analysis stage has been reported as the most important prognostic factor [55] and predictor of patient outcome [74].…”

Section: Prognosismentioning

confidence: 99%

Uterine Carcinosarcomas (Malignant Mixed Müllerian Tumours): A Review with Special Emphasis on the Controversies in Management

Kanthan

Senger

2011

Obstetrics and Gynecology International

106

View full text Add to dashboard Cite

Uterine carcinosarcomas (MMMT—malignant mixed Müllerian tumours) are highly aggressive, rare, biphasic tumours composed of epithelial and mesenchymal elements believed to arise from a monoclonal origin. While hysterectomy with bilateral salpingo-oophorectomy remains the mainstay treatment, high rates of recurrence and metastases suggest a need for lymphadenectomy and postoperative adjuvant treatment. There are no established consensus guidelines for therapeutic patient management. Though well recognized that it improves locoregional control, the role of radiation in improving overall survival outcomes remains undecided. Although various combinations of chemotherapy have been explored, an optimal therapeutic modality is yet to be determined. As overall survival rates have not improved in thirty years, it is suggested that targeted chemotherapy and/or a multimodality approach may yield better outcomes. This paper provides a summary of the aetiopathogenesis of carcinosarcomas (MMMT) limited to the uterus with special emphasis on the controversies in the management of these patients.

show abstract

Section: Prognosismentioning

confidence: 99%

Uterine Carcinosarcomas (Malignant Mixed Müllerian Tumours): A Review with Special Emphasis on the Controversies in Management

Kanthan

Senger

2011

Obstetrics and Gynecology International

106

View full text Add to dashboard Cite

show abstract

Tamoxifen in breast cancer ipse dixit in uterine malignant mixed Müllerian tumor and sarcoma—A report of 8 cases and review of the literature

Vasconcelos

Nunes

Duarte

et al. 2013

Reports of Practical Oncology & Radiotherapy

View full text Add to dashboard Cite

show abstract

Malignant Mixed Müllerian Tumour of the Uterus: Analysis of 44 Cases

et al. 2017

View full text Add to dashboard Cite

Objectives: The aim of our study was to evaluate the clinicopathological features and prognostic factors of uterine carcinosarcoma. Patients and Methods: In this retrospective study, the clinical characteristics of 44 patients with uterine MMMT were evaluated. Survival curves were estimated by the Kaplan-Meier method and compared by the log-rank test. Results: Forty-four patients with uterine carcinosarcoma were referred to our unit between 1995 and 2015. Their median age was 66.5 years. All women underwent total abdominal hysterectomy and bilateral salpingo-oophorectomy. Twenty-five percent had omental resection. Pelvic lymphadenectomy was performed in 18.2% of the cases. Twenty-six of the patients presented with stage I/II disease, 17 with advanced stages. In 20.5% of the cases there were metastases at diagnosis. Forty women received adjuvant chemotherapy, with complete remission in 67.9% of the cases. Recurrences were observed in 27.3% of the women. Disease-free and overall survival was 27 and 103 months, respectively. The FIGO stage, histological type, tumour size, chemotherapy regimen, pelvic lymphadenectomy, and myometrial invasion did not affect survival. Conclusions: Uterine MMMT is an aggressive tumour, often diagnosed at an advanced stage and with a high rate of metastases or recurrences. Because of its rarity, its management is controversial and fixed prognostic factors cannot be defined.

show abstract

Malignant mixed Müllerian tumor of the uterus associated with tamoxifen therapy for breast cancer

Cited by 4 publications

References 0 publications

Uterine Carcinosarcomas (Malignant Mixed Müllerian Tumours): A Review with Special Emphasis on the Controversies in Management

Uterine Carcinosarcomas (Malignant Mixed Müllerian Tumours): A Review with Special Emphasis on the Controversies in Management

Tamoxifen in breast cancer ipse dixit in uterine malignant mixed Müllerian tumor and sarcoma—A report of 8 cases and review of the literature

Malignant Mixed Müllerian Tumour of the Uterus: Analysis of 44 Cases

Contact Info

Product

Resources

About